EUVIMEDEUVIMED entdecken
Crossref

In Brief: RSV Vaccine (Arexvy) for Ages 18-49

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · 77-78

DOI: 10.58347/tml.2026.1754d ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has expanded the licensed use of the recombinant respiratory syncytial virus (RSV) vaccine Arexvy (GSK) to include adults 18-49 years old. Arexvy and the two other available RSV vaccines, Abrysvo and mResvia, are now all licensed for prevention of RSV lower respiratory tract disease in persons ≥60 years old and in those 18-59 years old who are at increased risk of lower respiratory tract disease caused by RSV.1 Abrysvo is also licensed for use in pregnant women at 32-36 weeks' gestation to prevent RSV-associated respiratory tract disease in their infants from birth to 6 months.

Schlagwörter

Stichwörter der Autor:innen

AbrysvoArexvyRSVadverse effectsdosageefficacymResviasafetyvaccine

Zitieren

APA

(2026). In Brief: RSV Vaccine (Arexvy) for Ages 18-49. The Medical Letter on Drugs and Therapeutics, 68(1754), 77-78. https://doi.org/10.58347/tml.2026.1754d

Vancouver

In Brief: RSV Vaccine (Arexvy) for Ages 18-49. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):77-78. doi:10.58347/tml.2026.1754d

BibTeX
@article{euvimed2026,
  title = {In Brief: RSV Vaccine (Arexvy) for Ages 18-49},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1754},
  pages = {77--78},
  doi = {10.58347/tml.2026.1754d}
}
Kostenlos starten →